ARCHIVES

Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Workshop Suggests Confirmation of Vitamin C Studies

December 7, 1990

ACCR Considers Foriend Membership, Meeting With ASCO

June 14, 1991

FDA Committee Oks AMSA for Group C List, Tables THC Request, Deadlocks On Estramustine NDA

July 3, 1981

Symptoms Don’t Help Detect Early-Stage Ovarian Cancer

February 26, 2010

Contract Awards: Texas Group Receives $472,000 To Monitor Asbestos Workers

August 23, 1974

CPRIT Likely to Get Funding For Two Years; DePinho Announces Austerity Measures

May 17, 2013